Keynote Speaker: Meaning Making, What The Research Shows
Despite years of study and training, Stephen Ross, MD was surprised and intrigued when he heard of the promising therapeutic results found in psychedelic trials done prior to the 1970s. Join Stephen as he highlights the groundbreaking research—both current and past— into how psychedelic therapies can reduce pain and suffering at end of life and during other times of physical and psychological distress.
Dr. Stephen Ross, Chair of the Scientific Advisory Board for Reset Pharma, Research Associate Professor of Psychiatry and Child & Adolescent Psychiatry at the NYU Grossman School of Medicine, is a founding member of the NYU Psychedelic Research Group, associate director of the NYU Langone Health (NYULH) Center for Psychedelic Medicine and director of the NYULH Psychedelic Medicine Research Training Program. He is principal or co-principal investigator on several studies at NYULH including phase II RCT of psilocybin-assisted psychotherapy in patients with life-threatening cancer-related psychiatric and existential distress, phase I/II RCT of LSD-assisted psychotherapy in advanced cancer pain syndromes, phase II RCT of psilocybin-assisted psychotherapy in alcohol use disorder, phase I/II controlled trial administering psilocybin to religious professionals, and phase II RCT of psilocybin treatment for Major Depressive Disorder, phase II/III trials of MDMA-assisted psychotherapy for PTSD, and is an expert in cannabinoid therapeutics.